BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Get the latest news on biotech funding, stocks, mergers and acquisitions, IPOs, bankruptcies, and more from BioSpace.

2024年7月23日 · BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

2025年3月25日 · BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

3 天之前 · Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.

2024年12月31日 · The news comes a little over a month after a second-quarter 2024 earnings report showed that despite pioneering gene therapies for several diseases, the biotech has had difficulty starting enough patients on its treatments.

2025年3月25日 · Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected Ebvallo, a T cell therapy approved in Europe for a transplant-related blood cancer, and placed a clinical hold on the company’s active drug applications.

2025年3月6日 · BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

2024年8月2日 · As part of a major reorganization, Vir Biotechnology has discontinued the bulk of its virology work and pivoted to cancer in an exclusive licensing deal with Sanofi.